A longitudinal study of serum 25-hydroxyvitamin D and intact parathyroid hormone levels indicate the importance of vitamin D and calcium homeostasis regulation in multiple sclerosis

Background: Past sun exposure and vitamin D3 supplementation have been associated with a reduced risk of multiple sclerosis (MS). There are no previous longitudinal studies of vitamin D in MS. Objectives: To compare regulation of vitamin D and calcium homeostasis between patients with MS and healthy controls. To study the correlation of parameters of vitamin D metabolism with MS activity. Methods: We measured 25-hydroxyvitamin D (25(OH)D), parathyroid hormone (PTH), calcium, phosphate, magnesium, chloride, alkaline phosphatase, albumin and thyroid stimulating hormone in serum every 3 months and at the time of relapse over 1 year in 23 patients with MS and in 23 healthy controls. MRI burden of disease and T2 activity were assessed every 6 months. Results: Vitamin D deficiency (S-25(OH)D ⩽37 nmol/l) was common, affecting half of the patients and controls at some time in the year. Seasonal variation of 25(OH)D was similar in patients and controls, but 25(OH)D serum levels were lower and intact PTH (iPTH) serum levels were higher during MS relapses than in remission. All 21 relapses during the study occurred at serum iPTH levels >20 ng/l (2.2 pmol/l), whereas 38% of patients in remission had iPTH levels ⩽20 ng/l. Patients with MS had a relative hypocalcaemia and a blunted PTH response in the winter. There was no correlation between serum 25(OH)D and MRI parameters. Conclusions: The endocrine circuitry regulating serum calcium may be altered in MS. There is an inverse relationship between serum vitamin D level and MS clinical activity. The role of vitamin D in MS must be explored further.

[1]  A. Ascherio,et al.  Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. , 2006, JAMA.

[2]  G. Rice,et al.  A pilot study of oral calcitriol (1,25-dihydroxyvitamin D3) for relapsing–remitting multiple sclerosis , 2005, Journal of Neurology, Neurosurgery & Psychiatry.

[3]  L. Airas,et al.  25-Hydroxyvitamin D levels in serum at the onset of multiple sclerosis , 2005, Multiple sclerosis.

[4]  P. Lips,et al.  Estimates of optimal vitamin D status , 2005, Osteoporosis International.

[5]  H. Jha,et al.  Novel tempeh (fermented soyabean) isoflavones inhibit in vivo angiogenesis in the chicken chorioallantoic membrane assay , 2005, British Journal of Nutrition.

[6]  B. Hollis Circulating 25-hydroxyvitamin D levels indicative of vitamin D sufficiency: implications for establishing a new effective dietary intake recommendation for vitamin D. , 2005, The Journal of nutrition.

[7]  J. McGrath,et al.  Distribution of the Vitamin D receptor and 1α-hydroxylase in human brain , 2005, Journal of Chemical Neuroanatomy.

[8]  Yan Zhu,et al.  Calcium and 1α,25‐dihydroxyvitamin D3 target the TNF‐α pathway to suppress experimental inflammatory bowel disease , 2005 .

[9]  Yan Zhu,et al.  Calcium and 1 alpha,25-dihydroxyvitamin D3 target the TNF-alpha pathway to suppress experimental inflammatory bowel disease. , 2005, European journal of immunology.

[10]  Steven A. Smith,et al.  Distribution of the vitamin D receptor and 1 alpha-hydroxylase in human brain. , 2005, Journal of chemical neuroanatomy.

[11]  P. Rothwell,et al.  Timing of birth and risk of multiple sclerosis: population based study , 2004, BMJ : British Medical Journal.

[12]  M. Cantorna,et al.  Mounting Evidence for Vitamin D as an Environmental Factor Affecting Autoimmune Disease Prevalence , 2004, Experimental biology and medicine.

[13]  A. Sadovnick,et al.  Vitamin D intake and incidence of multiple sclerosis , 2004, Neurology.

[14]  Jonne Vaarno,et al.  Fluorescent nanoparticles as labels for immunometric assay of C-reactive protein using two-photon excitation assay technology. , 2004, Analytical biochemistry.

[15]  H. Suominen,et al.  Vitamin D status as a determinant of peak bone mass in young Finnish men. , 2004, The Journal of clinical endocrinology and metabolism.

[16]  M. Uskoković,et al.  Tolerogenic dendritic cells induced by vitamin D receptor ligands enhance regulatory T cells inhibiting allograft rejection and autoimmune diseases. , 2004, Journal of cellular biochemistry.

[17]  T. Dwyer,et al.  Past exposure to sun, skin phenotype, and risk of multiple sclerosis: case-control study , 2003, BMJ : British Medical Journal.

[18]  M. Uskoković,et al.  Tolerogenic dendritic cells induced by vitamin D receptor ligands enhance regulatory T cells inhibiting allograft rejection and autoimmune diseases , 2003 .

[19]  M. Hakama,et al.  Multiple sclerosis in Finland: incidence trends and differences in relapsing remitting and primary progressive disease courses , 2003, Journal of neurology, neurosurgery, and psychiatry.

[20]  Elina Hyppönen,et al.  Intake of vitamin D and risk of type 1 diabetes: a birth-cohort study , 2001, The Lancet.

[21]  Richard A. C. Hughes,et al.  PRISMS-4: Long-term efficacy of interferon-&bgr;-1a in relapsing MS , 2001, Neurology.

[22]  M. Välimäki,et al.  A high prevalence of hypovitaminosis D in Finnish medical in‐ and outpatients , 2001, Journal of internal medicine.

[23]  C. Hayes Vitamin D: a natural inhibitor of multiple sclerosis , 2000, Proceedings of the Nutrition Society.

[24]  R. Vieth,et al.  Vitamin D and seasonal fluctuations of gadolinium‐enhancing magnetic resonance imaging lesions in multiple sclerosis , 2000, Annals of neurology.

[25]  C. Gössl,et al.  Seasonal fluctuations of gadolinium‐enhancing magnetic resonance imaging lesions in multiple sclerosis , 2000, Annals of neurology.

[26]  G. Ebers,et al.  Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis , 1998, The Lancet.

[27]  E. Gunter,et al.  Hypovitaminosis D in medical inpatients. , 1998, The New England journal of medicine.

[28]  Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. , 1998, Lancet.

[29]  S. Ralston,et al.  Nitric oxide and bone , 2001, Immunology.

[30]  R. Sandyk,et al.  Multiple sclerosis: relationship between seasonal variations of relapse and age of onset. , 1993, The International journal of neuroscience.

[31]  A. Ziegler,et al.  Changes of vitamin D3 serum concentrations at the onset of immune-mediated type 1 (insulin-dependent) diabetes mellitus. , 1991, Diabetes research.

[32]  R. Williams,et al.  Williams Textbook of endocrinology , 1985 .

[33]  S. Manolagas,et al.  1,25-dihydroxyvitamin D3 receptors in human leukocytes. , 1983, Science.

[34]  M. Alter,et al.  Multiple sclerosis and nutrition. , 1974, Archives of neurology.

[35]  Kh G Khodos [On the geography of multiple sclerosis]. , 1960, Zhurnal nevropatologii i psikhiatrii imeni S.S. Korsakova.

[36]  M. Folan Immunological Tolerance , 1956, Journal of the Irish Medical Association.

[37]  W. L. Benedict,et al.  Multiple Sclerosis , 2007, Journal - Michigan State Medical Society.